University cannabis course on medical cannabis first in France

Beginning earl next year, the University of Montpellier-Nîmes in the Gard department in France, is set to deliver a first of its kind medical cannabis certification. The course is aimed at professionals working in the healthcare field. The course is being delivered in anticipation of the upcoming legalization of medical cannabis research in France, due to take effect by the end of 2021.

Beginning in early in 2021, the Faculty of Medicine at the University of Montpellier-Nimes will offer a course. This course will provide theoretical and practical training in the administration of products containing cannabis. This will lead to the first university certificate in medical cannabis.

Due to COVID-19, the new cannabis certificate will be delivered via remote learning

The new cannabis certificate on therapeutic cannabis administration will be delivered via videoconference because of the coronavirus pandemic. The university course aims to provide theoretical and practical university training in the administration of products containing cannabis. It is being offered in anticipation of the legalization of medical cannabis research in France, which is planned to take place at the end of 2021. It will provide interdisciplinary knowledge for the prescription and support of patients suffering from pathologies requiring the use of medical cannabis.

Cannabis certificate details

The cannabis certificate course will last fifty hours and will be given by Professor Pierre Labauge from the University Hospital of Montpellier. Professor Amine Benyamina from the University of Paris Sud will also be present.

The course seeks to deliver training with medical cannabis and its related products. One of the objectives of the course will be for students to be able to identify patients who are eligible to be prescribed medical cannabis products.

Additionally, the course is designed to help medical professionals learn when and how to prescribe medical cannabis, and for pharmacists to learn how to dispense it. Dose control and dispensing of cannabis products will be other key topics in the course.

Of course, educating students on the different effects of therapeutic cannabis, as well as its different uses, will also be a focus of the cannabis course. The course will terminate with a final examination and a thesis on medical cannabis.

Registration of participants in cannabis course

In order to authorize the registration of those interested in the course, it will be essential for prospective students to fill out a pre-registration file. In addition to the corresponding authorization for registration, they must include a curriculum vitae, a letter of presentation, and a copy of the diplomas they hold. The course will be limited to a maximum number of students, so it is expected that the number of places will be filled quickly; speed in applying will be rewarded.

French experiment with medical cannabis

A few weeks ago, France proposed by decree that in 2021 a pilot experiment with medical cannabis will be legalized. French citizens had long awaited the decision of the French executive. More than three thousand French patients will have access to newly authorized experimentation with medical cannabis.

Moreover, they will be monitored by professionals who will be given academic training in cannabis. These trained professionals will come from courses that are currently being launched, like this cannabis course at the University of Montpellier-Nimes. Also, it will count on the cannabis companies participating in this French pilot program.

Another advantage for the participants of this experiment will be the fact that the products will be free for the duration of the trial. The products will meet pharmaceutical standards, including Good Manufacturing Practices (GMP).

A cannabis course is not the only French cannabis news

It is not only the cannabis course that is making French cannabis news. A few days ago, the European High Court of Justice ruled that cannabidiol, or CBD, was not a narcotic. The decision by the Luxembourg-based High Court (ECJ) was a setback for French justice, which sought to ban CBD products imported from another European nation.

Products legally produced in one EU country cannot be banned by another EU country if the product is not considered a narcotic. As is the case with the CBD, its import and sale could only be prohibited if the product was found to be harmful to health.

—

(Featured image by Yann Caradec (CC BY-SA 2.0) via Wikimedia Commons)

DISCLAIMER:

This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in La Marihuana, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.